Vendor Intelligence Report: EZ Peptides

Published 3 Jul 2026. 26-page investigative report on who is behind EZ Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 7 Finnrick lab tests, EZ Peptides shows a 57% overall pass rate, with 4 passes and 3 failures. The current slug-level record covers Retatrutide only, and it reads mixed: more informative than an untested Discord seller, but weaker than vendor-product pairs that pass consistently. The methodology chart also makes this a verify-the-current-batch signal, not a blanket endorsement.

The sharper buyer issue is attribution. The supplied Finnrick endpoints point to a Discord vendor, ezpeps.com, and @ezpeptides, but field records split those clues across two similarly named operations. Website footers, a Florida LLC filing, TikTok operator accounts, and a New Mexico-facing brand do not collapse into one clean channel, so COAs, coupons, reputation, and Finnrick signals can be imported from the wrong entity.

For ezpeps.com, the storefront has real operational positives: a broad COA library, Freedom Diagnostics verification links, Trustpilot engagement, and a conventional WooCommerce checkout. The same record documents an unsupported ISO/IEC 17025 claim, coded GLP product names on mainstream payment rails, mailbox-only disclosed addresses, and an unresolved public-operator versus filing-name split. Review sentiment is service-positive, but the report separates fast shipping and responsive support from laboratory evidence. For the rest of the catalog, Finnrick absence is treated as no independent coverage, not proof of failure.

Inside the full report:

  • Retatrutide pass/fail analysis and methodology-divergence charts
  • Corporate filings, website footer records, and mailbox-address review
  • ezpeps.com versus ezpeptides.com channel-disambiguation matrix
  • Freedom Diagnostics COA workflow and ISO/IEC 17025 claim analysis
  • Coded GLP checkout, Stripe/Square exposure, and affiliate-promotion scan
  • Trustpilot negative-review extracts and buyer verification checklist

Risk assessment

  • Testing-claim misrepresentation risk — high: ezpeps.com claims ISO 17025 lab; Freedom Diagnostics materials reviewed state ISO 9001/GLP only, affecting all products marketed under that banner.
  • Retatrutide reliability and test-attribution risk — medium: Finnrick slug record is Retatrutide only: 7 tests (4 pass / 3 fail), 71.65%, with attribution ambiguity between ezpeps.com and ezpeptides.com.
  • Brand-confusion and channel-authentication risk — medium: ezpeps.com and ezpeptides.com are separate operations; @ezpeptides/Finnrick/affiliate signals cross-map, and official anti-counterfeit guidance is incomplete.
  • Payment-processor evasion risk — medium: GLP-1-SG, GLP-2-TZ and GLP-3-RT are coded names sold through Stripe/Square checkout, raising interruption and recourse risk for those products.
  • Identity and operating-footprint opacity risk — medium: Public operator is Mike, Florida filing lists Thomas Johnston Jr.; website/filing names differ and both disclosed addresses are mailboxes.
  • Undisclosed affiliate-promotion risk — medium: Scan found 18 code/link-carrying promoters for the EZ Peptides brand; only 4 disclosed, 10 did not, and 4 were unclear.